KONEXBiotech & Pharma296160

ProGen

₩1,750▼ 3.21%2026-11-18 close
Market Cap
₩26.9B
Turnover
₩30,192,852
Volume
20K
Shares out.
15.4M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

One Lead Asset, Funding as the Swing Factor

ProGen is a Konex-listed biotech whose story rests on the clinical progress of its GLP-1/GLP-2 dual agonist PG-102, its pending KOSDAQ transfer and its funding needs.

  1. 1

    The flagship PG-102 is a GLP-1/GLP-2 dual agonist built on the NTIG platform, and its type 2 diabetes Phase 2a results were presented at ADA 2026.

  2. 2

    Standalone 2025 figures were reported as revenue of 885, operating loss of 17,291 and net loss of 20,092 (in KRW millions).

  3. 3

    Revenue is limited to small technology-transfer and service income, while R&D spending has grown as trials advanced.

  4. 4

    A KOSDAQ transfer and licensing talks are under way, but the transfer timeline has slipped from earlier targets.

  5. 5

    The share price moved from KRW 6,170 on March 31, 2026 to KRW 2,055 on October 27, 2026, and Konex trading value is thin.

02

Business structure

ProGen is a drug developer building its pipeline on NTIG, a long-acting, multi-target fusion protein platform. It develops metabolic disease therapeutics and constructs its pipeline on the NTIG platform. It listed on the Konex market on November 15, 2023.

The lead candidate PG-102 is a GLP-1/GLP-2 dual agonist using the NTIG platform, under development as a monthly injectable and a weekly oral diabetes and obesity treatment. PG-102 is a pipeline asset for which ProGen holds a worldwide exclusive license for development and commercialization from SL Bigen. The oral form RPG-102 is a candidate co-developed with Rani Therapeutics of the United States.

Revenue comes from technology transfer and research services rather than product sales.

Of the KRW 1.1 billion in 2023 revenue, NTIG platform income was KRW 0.3 billion, Super EGF KRW 0.1 billion, the IgE Trap technology transfer KRW 0.4 billion, metabolic disease substances KRW 0.25 billion and general research services KRW 0.05 billion.

This mix shows that the business is still at a pre-commercial research stage. The collaboration scope is broad.

In 2024 ProGen signed an immune-disease ADC joint research deal with Dong-A ST's Aptis, an ADC joint research deal with Lanova Medicines, an oral obesity co-development deal with Rani and a dual-target immuno-oncology joint research deal with Yuhan.

On the competitive front, large GLP-1 drugs such as semaglutide and tirzepatide are the reference points. Besides ProGen, Zealand Pharma of Denmark is cited as developing a GLP-1/GLP-2 dual agonist.

The company points to muscle preservation, gastrointestinal tolerability and longer dosing intervals as differentiators, but these still need continued clinical validation. It is described as an affiliate of Yuhan, and it has attracted investment from Yuhan and JW Pharmaceutical, among others.

03

Recent trends

Earnings continue to show losses. For 2025 on a standalone basis, the filing showed revenue of 885, operating income of -17,291, net income of -20,092, total assets of 170,610, total liabilities of 124,435 and total equity of 46,175, and earnings per share were also negative.

The figures appear to be in KRW millions, which means an operating loss of 17,291 and a net loss of 20,092. Total liabilities exceed total equity. For comparison, per FnGuide data, the 2024 operating loss was KRW 167 billion. Annual R&D spending rose from KRW 5.6 billion in 2022 and KRW 5.8 billion in 2023 to KRW 13.7 billion in 2024.

Clinical progress is visible. Topline PG-102 Phase 2a data in type 2 diabetes were presented at AIBIS, with 48 patients enrolled. Press coverage at the time reported a maximum HbA1c reduction of 1.44%.

At ADA 2026, glycemic improvement, fat-centered body composition improvement and gastrointestinal tolerability were reported, and no vomiting was reported in the monthly dosing group.

As a follow-up, the Ministry of Food and Drug Safety approved a high-dose Phase 1 trial, designed as 12-week repeated dosing in obese subjects to confirm the dose-response relationship.

There were also funding and governance developments. ProGen raised KRW 22 billion, made up of KRW 8 billion in convertible preferred shares and KRW 14 billion in convertible bonds.

It later issued KRW 2.8 billion in convertible bonds to its largest shareholder Yuhan and founder Young-Chul Sung, the former Genexine chairman. At the March 31, 2026 shareholder meeting, President Byung-Hwa Lee was newly elected as an inside director.

He bought 5,000 common shares on the market between May 6 and May 8, 2026. The share price has trended lower. The March 31, 2026 close was KRW 6,170, the intraday price on May 13, 2026 was KRW 4,695, and the price on October 8, 2026 was reported at KRW 2,300.

The October 27, 2026 close was KRW 2,055, with a market capitalization of KRW 31.6 billion and trading value of KRW 10,784,836.

04

Outlook

There are three near-term items to watch. The first is the KOSDAQ transfer process. Dailypharm reported that the company is targeting a technology evaluation within the year, based on the PG-102 Phase 2 data. According to Sisa Journal e, the transfer timing had earlier been pushed back from the original plan. The repeated delay is a fact the market has to weigh.

The second is clinical expansion. The follow-up high-dose Phase 1 trial aims to confirm weight-loss effect and dose-response through 12-week repeated dosing. The company intends to use the result as a basis for later development strategy and licensing talks.

Company staff said they are preparing a technology-special listing while discussing licensing with domestic and overseas firms. Licensing timing and size are hard to predict. On reported figures, revenue is small, so the pattern of covering trial costs with external funding is likely to continue for some time.

The third is the oral form and the competitive landscape. Rani Therapeutics announced initial Phase 1a results for RPG-102, an oral GLP-1/GLP-2 dual agonist. Meanwhile, competition in oral obesity drugs is moving quickly, led by large pharmaceutical companies.

The press described the oral obesity drug race as entering a second round. In this setting, the key test is whether muscle preservation and dosing convenience are supported by comparative clinical data. Shareholder changes and financing terms may also affect the pace of development, so disclosures need to be tracked.

05

Bull factors

Clinical progress with a differentiated mechanism

PG-102 is a dual agonist that targets GLP-1 and GLP-2 at the same time. In Phase 2a, glycemic improvement, fat-centered body composition improvement and gastrointestinal tolerability were reported, with no vomiting in the monthly group.

The Phase 1 study confirmed safety and tolerability in 98 people, and obese patients showed weight loss of up to 10.7%. If muscle preservation and longer dosing intervals carry through in data, they could form a basis for comparison with existing GLP-1 drugs.

KOSDAQ transfer and licensing options

The company is pursuing a KOSDAQ transfer and licensing in parallel, based on its clinical results. Company staff said they are preparing a technology-special listing while discussing licensing with domestic and overseas firms.

The company brought in President Byung-Hwa Lee, who has led two Konex-to-KOSDAQ transfers, as CFO and COO. If either path becomes concrete, the funding burden could change.

Backing from shareholders and partners

ProGen is described as an affiliate of Yuhan, and it secured working capital through convertible bonds issued to Yuhan and its founder. In oral development, it has a co-development structure with Rani Therapeutics.

In a beagle preclinical study, oral PG-102 recorded an average bioavailability of 111% versus the injectable. Co-development shares the development burden, which differs from going alone.

06

Bear factors

Minimal revenue and persistent losses

On a standalone basis for 2025, revenue was 885 against an operating loss of 17,291 and a net loss of 20,092. Revenue is limited to licensing and services and cannot cover the losses. R&D spending rose to KRW 13.7 billion in 2024. Cost pressure could grow further as trials advance.

Delayed transfer and thin liquidity

A Korea IR Service report described targets of a technology evaluation in the first half of 2025 and a preliminary listing review request within that year. However, ProGen remains on Konex as of October 27, 2026. Trading value that day was only KRW 10,784,836. With such thin trading, even small orders can move the price sharply.

Intense competition and validation tasks

Large GLP-1 drugs have taken an early lead in the obesity and diabetes market. Press coverage described the oral obesity drug competition as entering a second round. ProGen is at the stage of checking maximum weight-loss potential through a high-dose follow-up trial. Uncertainty therefore remains until its differentiation is proven with comparative data.

07

Risk factors

Macro

Drug developers are sensitive to sentiment toward the biotech sector. ProGen also referred to subdued investor sentiment across pharma and biotech when it raised funds. Weaker sentiment can worsen the terms of external funding such as equity and convertible bonds. The small trading scale of the Konex market could amplify this effect.

Clinical and regulatory

Company value is concentrated in the single candidate PG-102. If the expected weight loss or tolerability is not confirmed in the high-dose follow-up trial, the development plan could change. The unpredictable timing and size of licensing deals is another burden. A KOSDAQ transfer also requires passing a technology evaluation and a listing review.

Financial and governance

Standalone total liabilities for 2025 were 124,435, larger than total equity of 46,175. Major shareholder SL Bigen held 28.91% in the April 6, 2026 report, down from 30.14% in the prior report. The same report lists a pledge on shares to Genexine and a call option with PT Kalbe Farma. These ownership changes and collateral and option contracts should be tracked in future disclosures.

08

Overall view

ProGen is a Konex-listed drug developer whose business value is concentrated in PG-102, a GLP-1/GLP-2 dual agonist. Phase 2a data on glucose, body composition and tolerability have been presented, and a high-dose follow-up trial has been approved.

On the other hand, reported revenue is small, operating and net losses continue, and total liabilities exceed total equity. The KOSDAQ transfer has slipped from earlier targets, and Konex trading value is small. The share price moved from KRW 6,170 on March 31, 2026 to KRW 2,055 on October 27, 2026.

This can be read as reflecting both clinical progress and uncertainty over funding and timing, but its direction cannot be determined. This report is for information only, and the investment judgment rests with the reader.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. news.nate.com
  2. comp.fnguide.com
  3. kind.krx.co.kr
  4. digitaltoday.co.kr
  5. digitaltoday.co.kr
  6. pharm.edaily.co.kr
  7. dailypharm.com
  8. dailypharm.com
  9. thebionews.net
  10. medigatenews.com
  11. news1.kr
  12. biotimes.co.kr
  13. sisajournal-e.com
  14. ebn.co.kr
  15. pharm.edaily.co.kr
  16. investing.com
  17. thevc.kr

Report written 2026-10-27 · Data as of 2026-10-26

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis